Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study

INTRODUCTION: The aim of this study was to assess long-term golimumab therapy in rheumatoid arthritis (RA) patients who discontinued previous tumor necrosis factor-α (TNF)-inhibitor(s). METHODS: Patients enrolled into this multicenter, randomized, double-blind, placebo-controlled study of active RA...

Descripción completa

Detalles Bibliográficos
Autores principales: Smolen, Josef S, Kay, Jonathan, Doyle, Mittie, Landewé, Robert, Matteson, Eric L, Gaylis, Norman, Wollenhaupt, Jürgen, Murphy, Frederick T, Xu, Stephen, Zhou, Yiying, Hsia, Elizabeth C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382834/
https://www.ncbi.nlm.nih.gov/pubmed/25627338
http://dx.doi.org/10.1186/s13075-015-0516-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382834/
https://www.ncbi.nlm.nih.gov/pubmed/25627338
http://dx.doi.org/10.1186/s13075-015-0516-6

Ejemplares similares